Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province, Br J Ind Med, vol.17, pp.260-71, 1960. ,
Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies, Clin Chest Med, vol.34, pp.99-111, 2013. ,
Management of malignant pleural mesothelioma-The European experience, Journal of thoracic disease, vol.6, issue.2, pp.238-52, 2014. ,
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know, Eur J Cardiothorac Surg, vol.46, pp.602-608, 2014. ,
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study, Lancet Oncol, vol.12, pp.763-72, 2011. ,
Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis, Thorax, vol.69, pp.843-50, 2014. ,
The global spread of asbestos, Ann Glob Health, vol.80, pp.257-62, 2014. ,
, Asbestos in Asia. Respirology, 2015.
Global mesothelioma epidemic: Trend and features. Indian journal of occupational and environmental medicine, vol.18, pp.82-90, 2014. ,
Thoracic Neoplasia-Mesothelioma, Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms, pp.2690-700, 2014. ,
Effets sur la santé des fibres minérales artificielles. ECM -Pathologie professionnelle et de l'environnement, vol.9, pp.1-8, 2014. ,
Malignant mesothelioma: facts, myths, and hypotheses, J Cell Physiol, vol.227, pp.44-58, 2012. ,
Molecular pathogenesis of malignant mesothelioma, Expert Rev Mol Med, vol.14, p.12, 2012. ,
Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting, Arch Pathol Lab Med, vol.136, pp.450-457, 2011. ,
Cancer stem cell plasticity and tumor hierarchy, World journal of stem cells, vol.7, pp.27-36, 2015. ,
Heterogeneity in cancer: cancer stem cells versus clonal evolution, Cell, vol.138, pp.822-831, 2009. ,
Accessories to the crime: functions of cells recruited to the tumor microenvironment, Cancer Cell, vol.21, pp.309-331, 2012. ,
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, 2013. ,
Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-93, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478588
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling, Am J Pathol, vol.166, pp.1827-1867, 2005. ,
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma, Chest, vol.125, pp.1843-52, 2004. ,
Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-tomesenchymal transition, Clin Cancer Res, vol.20, pp.1323-1357, 2014. ,
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nat Genet, vol.43, pp.668-72, 2011. ,
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma, Am J Pathol, vol.178, pp.881-94, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00531343
Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma, Oncogene, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478602
Whole exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A and CUL1 in malignant pleural mesothelioma, Cancer Res, 2015. ,
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study, J Thorac Oncol, vol.10, pp.492-501, 2015. ,
Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing, J Thorac Oncol, vol.10, pp.844-51, 2015. ,
Cell signaling by receptor tyrosine kinases, Cell, vol.141, pp.1117-1151, 2010. ,
Reactive oxygen species in the activation of MAP kinases, Methods in enzymology, vol.528, pp.27-48, 2013. ,
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma, Lung Cancer, vol.54, pp.399-407, 2006. ,
Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma, J Clin Pathol, vol.65, pp.522-529, 2012. ,
Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma, Lung Cancer, vol.70, pp.43-50, 2010. ,
Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations, J Surg Oncol, vol.104, pp.701-706, 2011. ,
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma, Int J Cancer, vol.118, pp.521-523, 2006. ,
Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma, Br J Cancer, vol.108, pp.1743-1752, 2013. ,
Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma, J Thorac Oncol, vol.4, p.559, 2009. ,
Identification of actionable mutations in malignant pleural mesothelioma, Lung Cancer, vol.86, pp.35-40, 2014. ,
Diagnostic molecular pathology : the American journal of surgical pathology, 2014. ,
Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy, J Thorac Oncol, vol.6, pp.864-74, 2011. ,
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Mutagenesis, vol.28, pp.323-354, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478590
Update on the molecular biology of malignant mesothelioma, Cancer, vol.109, pp.1454-61, 2007. ,
Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines, Cancer Res, vol.47, pp.6180-6184, 1987. ,
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma, Clin Lung Cancer, vol.15, pp.197-201, 2014. ,
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma, Cancer Res, vol.66, pp.352-61, 2006. ,
AXL regulates mesothelioma proliferation and invasiveness, Oncogene, vol.30, pp.1643-52, 2011. ,
The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications, Int J Cancer, vol.134, pp.1024-1057, 2014. ,
Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma, Br J Cancer, vol.101, pp.424-455, 2009. ,
Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study, BMC research notes, vol.7, p.549, 2014. ,
Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma, Mol Cancer Res, vol.12, pp.1460-1469, 2014. ,
The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature, Arch Pathol Lab Med, vol.128, pp.538-581, 2004. ,
c-Kit is not expressed in malignant mesothelioma, Mod Pathol, vol.16, pp.818-840, 2003. ,
Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma, Neoplasia, vol.13, pp.12-22, 2011. ,
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells, Carcinogenesis, vol.30, pp.1097-105, 2009. ,
A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma, Genes Cancer, vol.1, pp.493-505, 2010. ,
Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells, Cancer, vol.103, pp.2427-2460, 2005. ,
Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates, Cell Death and Differentiation, vol.16, pp.1146-55, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00388174
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma, Br J Cancer, vol.110, pp.2479-88, 2014. ,
, Group I p21-Activated Kinases
, Promote Tumor Cell Proliferation and Survival through the AKT1 and Raf-MAPK Pathways, Mol Cancer Res, vol.10, pp.1178-88, 2012.
Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells, J Cell Physiol, vol.226, pp.762-770, 2011. ,
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair, Mol Cancer Ther, vol.12, pp.1073-84, 2013. ,
The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma, Biochim Biophys Acta, vol.1845, pp.232-279, 2014. ,
Activation of the PI3K-AKT pathway in human malignant mesothelioma cells, Molecular Medicine Reports, vol.2, pp.181-189, 2009. ,
PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis, Eur J Biochem, vol.263, pp.605-616, 1999. ,
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM), Lung Cancer, vol.77, pp.192-200, 2012. ,
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy, Lung Cancer, vol.78, pp.23-32, 2012. ,
Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth, Oncogene, vol.24, pp.6080-6089, 2005. ,
PTEN protein expression in malignant pleural mesothelioma, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.34, pp.847-51, 2013. ,
PTEN expression is a strong predictor of survival in mesothelioma patients, Eur J Cardiothorac Surg, vol.33, pp.502-508, 2008. ,
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma, PLoS ONE, vol.9, p.105919, 2014. ,
Translational control by oncogenic signaling pathways, Biochim Biophys Acta, 2014. ,
Targeting PI3K/Akt/mTOR Signaling in Cancer, Frontiers in oncology, vol.4, p.64, 2014. ,
mTOR signaling in tumorigenesis, Biochim Biophys Acta, vol.1846, pp.638-54, 2014. ,
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids, J Biol Chem, vol.283, pp.13021-1330, 2008. ,
Spreading of mesothelioma cells is rapamycinsensitive and requires continuing translation, J Cell Biochem, vol.108, pp.867-76, 2009. ,
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids, Am J Respir Cell Mol Biol, vol.39, pp.576-83, 2008. ,
Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma, PLoS ONE, vol.7, p.36856, 2012. ,
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling, Mol Cell Biol, vol.29, pp.4235-4284, 2009. ,
Molecular pathogenesis of malignant mesothelioma, Carcinogenesis, vol.34, pp.1413-1422, 2013. ,
Role of extracellular matrix and YAP/TAZ in cell fate determination, Cell Signal, vol.26, pp.186-91, 2014. ,
The biology of YAP/TAZ: hippo signaling and beyond, Physiol Rev, vol.94, pp.1287-312, 2014. ,
The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease, Development, vol.141, pp.1614-1640, 2014. ,
LATS2 Is a Tumor Suppressor Gene of Malignant Mesothelioma, Cancer Res, vol.71, pp.873-83, 2011. ,
YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes, Oncogene, vol.31, pp.5177-5199, 2012. ,
LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade, Oncogene, vol.34, pp.73-83, 2015. ,
CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis, Genes Chromosomes Cancer, vol.48, pp.615-638, 2009. ,
Functional inactivation of NF2/merlin in human mesothelioma, Lung Cancer, vol.64, pp.140-147, 2009. ,
Hedgehog signaling: From basic research to clinical applications, Journal of the Formosan Medical Association = Taiwan yi zhi, 2015. ,
Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma, PLoS ONE, vol.8, p.66685, 2013. ,
Gli as a novel therapeutic target in malignant pleural mesothelioma, PLoS ONE, vol.8, p.57346, 2013. ,
Role of hedgehog signaling in malignant pleural mesothelioma, Clin Cancer Res, vol.18, pp.4646-56, 2012. ,
Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro, J Thorac Cardiovasc Surg, vol.147, pp.508-524, 2014. ,
The Wnt signaling pathway in development and disease. Annual review of cell and developmental biology, vol.20, pp.781-810, 2004. ,
Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients. Experimental and therapeutic medicine, vol.3, pp.952-960, 2012. ,
Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells, Biochem Biophys Res Commun, vol.440, pp.82-89, 2013. ,
Wnt2 as a new therapeutic target in malignant pleural mesothelioma, Int J Cancer, vol.117, pp.326-358, 2005. ,
Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis, Cancer Res, vol.68, pp.8333-8374, 2008. ,
beta-catenin expression in benign and malignant pleural disorders, Int J Clin Exp Pathol, vol.4, pp.742-749, 2011. ,
Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma, Int J Cancer, vol.127, pp.2859-69, 2010. ,
Targeting the ubiquitin pathway for cancer treatment, Biochim Biophys Acta, vol.1855, pp.50-60, 2014. ,
Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression, Science signaling, vol.4, p.6, 2011. ,
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus, Cancer Cell, vol.26, pp.48-60, 2014. ,
mTOR signaling at a glance, J Cell Sci, vol.122, pp.3589-94, 2009. ,
Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma, Trends in pharmacological sciences, vol.32, pp.463-79, 2011. ,
Searching for targets for the systemic therapy of mesothelioma, Ann Oncol, 2015. ,
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial, Lung Cancer, vol.50, pp.83-89, 2005. ,
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies, Cancer Treat Rev, vol.41, pp.27-34, 2015. ,
SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM), J Thorac Oncol, vol.10, pp.387-91, 2015. ,
The concept of synthetic lethality in the context of anticancer therapy, Nat Rev Cancer, vol.5, pp.689-98, 2005. ,
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship, Science translational medicine, vol.6, pp.237-68, 2014. ,
Hippo/YAP pathway for targeted therapy, Translational lung cancer research, vol.3, pp.75-83, 2014. ,
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma, British journal of pharmacology, vol.166, pp.532-53, 2012. ,
Prognostic factors in malignant pleural mesothelioma, Hum Pathol, 2015. ,
Anti-angiogenic therapies for malignant pleural mesothelioma, Expert Opin Investig Drugs, vol.21, pp.833-877, 2012. ,
, , 1998.
, Annales de pathologie, vol.34, pp.51-63, 2014.
High-throughput oncogene mutation profiling in human cancer, Nat Genet, vol.39, pp.347-51, 2007. ,
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases, Microbiol Mol Biol Rev, vol.75, pp.50-83, 2011. ,
The hippo signaling pathway in development and cancer, Dev Cell, vol.19, pp.491-505, 2010. ,
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation, Pathol Int, vol.61, pp.331-375, 2011. ,